



BJA BUREAU OF JUSTICE ASSISTANCE

GMS Report Prescription Drug Monitoring Program 2015-PM-BX-0003 Reporting Period: July 1 - December 31, 2016

This report is generated for the Pennsylvania Department of Health grantee for federal award number 2015-PM-BX-0003. The award amount is \$ 409,949. It reflects performance measurement data for the period July 1 - December 31, 2016. Any funds reported only represent an estimate of dollars allocated or used for activities covered by this award.

In addition, the performance measurement data represented in this report is from activity that occurred under the following awards:

Federal Award Number	Federal Award Amount	Was There Any Activity From Jul - Dec 16
2015-PM-BX-0003	409,949	Yes All dispensers and pharmacies are required to report to the new PA PDMP system within 72 hours of dispensation of controlled substances (Schedule II to V) as of June 24, 2016. As of August 25, 2016, PA PDMP system is now available for patient query to all prescribers and pharmacists practicing in PA as well as their delegates. An amendment to the ABC-MAP Act 191 was passed on November 2, 2016 that requires dispensers to report no later than the close of subsequent business day. It also requires dispensers to check the PDMP system before dispensing an opioid drug product or a benzodiazepine prescribed to a patient if any of the following apply: 1.The patient is a new patient of the dispenser. 2.The patient pays cash when they have insurance. 3.The patient requests a refill early. 4.The patient is getting opioid drug products or benzodiazepines from more than one prescriber. It also required prescribers to check the PDMP system each time a patient is prescribed an opioid drug product or benzodiazepine by the prescriber. The effective date to the amended legislation is Jan 01, 2017.

This table will show all awards that were active during the reporting period. These awards may change as the reporting periods change.

Project Description

The Harold Rogers Prescription Drug Monitoring Program (PDMP) provides funding to allow state's discretion to plan, implement, or enhance a PDMP to accommodate local decision-making based on state laws and preferences, while encouraging the replication of promising practices. In FY 2015, the PDMP Program provides resources in four purpose areas to support the following: 1) statewide implementation and enhancement grants; 2) practitioner and research partnership cooperative agreements; 3) data-driven multi-disciplinary approaches to reducing prescription abuse cooperative agreements; and 4) tribal prescription drug monitoring data sharing grants. The Pennsylvania Department of Health will use the grant funds to focus on the program's main goals. The main goals are to establish and build a data collection and analysis system; develop an infrastructure to support programmatic activities; facilitate the exchange of information and collected prescription data and other scheduled chemical products among states; facilitate the establishment of collaborations; develop a training program for system users; produce and disseminate educational materials; and assess the efficiency and effectiveness of the program. Funds may also be used to enhance the functioning of a data collection and analysis system; enhance an existing educational or training program; support collaborations with law enforcement and prosecutors or public health officials; support collaborations with treatment providers and drug courts; facilitate electronic information sharing among states in compliance with the National PMIX Architecture; expand monitoring to Schedules II, III, IV, and V; develop or enhance the capacity to provide unsolicited reports of controlled substance prescribing to authorized individuals or entities; and assess the efficiency and effectiveness of the program. CA/NCF

Performance Measurement Data

Performance Measurement	Operational Activity	
	Jul - Sep 16	Oct - Dec 16
1. How many individuals are licensed in your state to prescribe controlled substances?	67,884	68,104
2. How many licensed prescribers have been formally trained to use the PDMP system (e.g., in a classroom setting)? Report the cumulative number of prescribers trained since the PDMP program became operational. Include all prescribers who were licensed at the time of training, regardless of their licensure status on the last day of the reporting period.	0	0
3. How many licensed prescribers have been informally trained to use the PDMP system (e.g., through information found in professional publications or online)? Report the cumulative number of prescribers trained since the PDMP program became operational. Include all prescribers who were licensed at the time of training, regardless of their licensure status on the last day of the reporting period.	37,681	68,104
4. How many pharmacists are licensed to dispense controlled substances in your state?	23,575	22,588
5. How many pharmacists licensed in your state have been formally trained to use the PDMP system (e.g., in a classroom setting)? Report the cumulative number of pharmacists trained since the PDMP program became operational. Include all pharmacists who were licensed at the time of training, regardless of their licensure status on the last day of the reporting period.	0	0
6. How many pharmacists licensed in your state have been informally trained to use the PDMP system (e.g., through information found in professional publications or online)? Report the cumulative number of pharmacists trained since the PDMP program became operational. Include all pharmacists who were licensed at the time of training, regardless of their licensure status on the last day of the reporting period.	8,200	22,588
7. How many investigators are authorized to use the PDMP system to conduct investigations for law enforcement or regulatory purposes?	48	87
8. How many of the investigators authorized to use the PDMP system have been formally trained to use the PDMP system (e.g., in a classroom setting)? Report the cumulative number of investigators trained since the PDMP program became operational. Include all investigators authorized to use the system at the time of training, regardless of their status on the last day of the reporting period.	48	87
9. How many of the investigators authorized to use the PDMP system have been informally trained to use the PDMP system (e.g., through information found in professional publications or online)? Report the cumulative number of investigators trained since the PDMP program became operational. Include all investigators authorized to use the system at the time of training, regardless of their status on the last day of the reporting period.	48	87
10. How many pharmacies are required to report in the PDMP system?	3,337	3,336
11. How many pharmacies reported to the PDMP at least once during the 3-month reporting period?	3,767	3,759

12. How many prescribers are registered to use the PDMP system?	38,670	45,866			
13. How many pharmacists are registered to use the PDMP system?	8,200	8,960			
14. How many authorized investigators accessed the PDMP during the 3-month reporting period?	48	58			
15. How many regulatory agencies accessed the PDMP at least once during the 3-month reporting period?	2	29			
Performance Measurement	Dispensing Information: All Schedules (3 Months)				
	Jul - Sep 16	Oct - Dec 16			
16. During the 3-month reporting period, how many adults received prescriptions for painkillers with a morphine equivalent greater than 100 mg per day?	174,875	155,734			
17. During the 3-month reporting period, how many youth received prescriptions for painkillers with a morphine equivalent greater than 100 mg per day?	370	343			
Schedule of Medication Filled			Number of Patients		
Jul - Sep 16					
18. How many patients filled prescriptions for scheduled medication during the 3-month reporting period?					
Schedule II			1,033,883		
Schedule II and/or III			1,184,902		
Schedule II, III, and/or IV			1,969,190		
Schedule of Medication Filled			Number of Patients		
Oct - Dec 16					
Schedule II			1,014,716		
Schedule II and/or III			1,160,273		
Schedule II, III, and/or IV			1,939,078		
Schedule of Medication Filled	Pain Relievers	Tranquilizers	Stimulants	Sedatives	Total
Jul - Sep 16					
19. How many doses were dispensed during the 3-month reporting period?					
Schedule II	79,116,556	0	19,511,256	0	98,627,812
Schedule III	10,267,584	173,465	0	3,296	10,444,345
Schedule IV	23,220	6,044,727	0	84,330,358	90,398,305
Schedule of Medication Filled	Pain Relievers	Tranquilizers	Stimulants	Sedatives	Total
Oct - Dec 16					
Schedule II	74,676,941	0	19,673,913	0	94,350,854
Schedule III	10,495,011	487,543	0	830	10,983,384
Schedule IV	25,940	6,768,005	293,402	83,369,146	90,456,493
Category	Threshold A: 5+ Prescribers and 5+ Pharmacies in 3 Months		Threshold B: 10+ Prescribers and 10+ Pharmacies in 3 Months		
Jul - Sep 16					
20. During the 3 months before the last day of the reporting period, how many patients exceeded thresholds A and B?					
Number of patients exceeding the thresholds for Schedule II drugs in the 3 months before the last day of the reporting period			789		

17

Category	Threshold A: 5+ Prescribers and 5+ Pharmacies in 3 Months	Threshold B: 10+ Prescribers and 10+ Pharmacies in 3 Months
Oct - Dec 16		
Number of patients exceeding the thresholds for Schedule II drugs in the 3 months before the last day of the reporting period	125	1
Schedule of Medication Filled	Threshold A: 5+ Prescribers and 5+ Pharmacies	Threshold B: 10+ Prescribers and 10+ Pharmacies
Jul - Sep 16		
21. During the 3 months before the last day of the reporting period, how many nonliquid doses of Schedule II prescription drugs were dispensed to patients exceeding thresholds A and B?		
Pain Relievers	160,327	4,660
Tranquilizers	0	0
Stimulants	21,562	0
Sedatives	0	0
The sum of Pain Relievers, Tranquilizers, Stimulants, and Sedatives for each Threshold should be less or equal to than the number reported for All Schedule II Drugs	181,889	4,660
All Schedule II Drugs : Include the number of Pain Relievers, Tranquilizers, Stimulants and Sedatives, as well as any other Schedule II drugs exceeding Thresholds A or B	181,889	4,660
Schedule of Medication Filled	Threshold A: 5+ Prescribers and 5+ Pharmacies	Threshold B: 10+ Prescribers and 10+ Pharmacies
Oct - Dec 16		
Pain Relievers	30,145	408
Tranquilizers	0	0
Stimulants	2,465	0
Sedatives	0	0
The sum of Pain Relievers, Tranquilizers, Stimulants, and Sedatives for each Threshold should be less or equal to than the number reported for All Schedule II Drugs	32,610	408
All Schedule II Drugs : Include the number of Pain Relievers, Tranquilizers, Stimulants and Sedatives, as well as any other Schedule II drugs exceeding Thresholds A or B	32,610	408
Category	Threshold A: 5+ Prescribers and 5+ Pharmacies in 3 Months	Threshold B: 10+ Prescribers and 10+ Pharmacies in 3 Months
Jul - Sep 16		
22. During the 3 months before the last day of the reporting period, how many patients exceeded thresholds A and B?		
Number of patients exceeding the thresholds for Schedule II and/or III drugs in the 3 months before last day of the reporting period	914	18
Category	Threshold A: 5+ Prescribers and 5+ Pharmacies in 3 Months	Threshold B: 10+ Prescribers and 10+ Pharmacies in 3 Months
Oct - Dec 16		
Number of patients exceeding the thresholds for Schedule II and/or III drugs in the 3 months before last day of the reporting period	215	1

Schedule of Medication Filled	Threshold A: 5+ Prescribers and 5+ Pharmacies	Threshold B: 10+ Prescribers and 10+ Pharmacies
Jul - Sep 16		
23. During the 3 months before the last day of the reporting period, how many nonliquid doses of Schedule II and/or III prescription drugs were dispensed to patients exceeding thresholds A and B?		
Pain Relievers	187,569	5,492
Tranquilizers	195	195
Stimulants	27,101	0
Sedatives	0	0
The sum of Pain Relievers, Tranquilizers, Stimulants, and Sedatives for each Threshold should be less or equal to than the number reported for All Schedule II and/or III Drugs	214,865	5,687
All Schedule II and/or III Drugs: Include the number of Pain Relievers, Tranquilizers, Stimulants and Sedatives, as well as any other Schedule II and/or III drugs exceeding Thresholds A or B	214,865	5,687
Schedule of Medication Filled	Threshold A: 5+ Prescribers and 5+ Pharmacies	Threshold B: 10+ Prescribers and 10+ Pharmacies
Oct - Dec 16		
Pain Relievers	46,376	408
Tranquilizers	608	0
Stimulants	7,035	0
Sedatives	0	0
The sum of Pain Relievers, Tranquilizers, Stimulants, and Sedatives for each Threshold should be less or equal to than the number reported for All Schedule II and/or III Drugs	54,019	408
All Schedule II and/or III Drugs: Include the number of Pain Relievers, Tranquilizers, Stimulants and Sedatives, as well as any other Schedule II and/or III drugs exceeding Thresholds A or B	54,019	408
Category	Threshold A: 5+ Prescribers and 5+ Pharmacies in 3 Months	Threshold B: 10+ Prescribers and 10+ Pharmacies in 3 Months
Jul - Sep 16		
24. How many patients exceeded thresholds A and B?		
Number of patients exceeding the thresholds for Schedule II, III, and/or IV drugs in the 3 months before the last day of the reporting period	1,149	31
Category	Threshold A: 5+ Prescribers and 5+ Pharmacies in 3 Months	Threshold B: 10+ Prescribers and 10+ Pharmacies in 3 Months
Oct - Dec 16		
Number of patients exceeding the thresholds for Schedule II, III, and/or IV drugs in the 3 months before the last day of the reporting period	502	1
Schedule of Medication Filled	Threshold A: 5+ Prescribers and 5+ Pharmacies	Threshold B: 10+ Prescribers and 10+ Pharmacies
Jul - Sep 16		
25. How many nonliquid doses of Schedule II, III, and/or IV prescription drugs were dispensed to patients exceeding thresholds A and B?		
Pain Relievers	285,876	7,300
Tranquilizers	9,983	565

Stimulants	37,860	0
Sedatives	153,655	1,979
The sum of Pain Relievers, Tranquilizers, Stimulants, and Sedatives for each Threshold should be less or equal to than the number reported for All Schedule II, III, and/or IV Drugs	487,374	9,844
All Schedule II, III, and/or IV Drugs: Include the number of Pain Relievers, Tranquilizers, Stimulants and Sedatives, as well as any other Schedule II, III, and/or IV drugs exceeding Thresholds A or B	487,374	9,844

Schedule of Medication Filled	Threshold A: 5+ Prescribers and 5+ Pharmacies	Threshold B: 10+ Prescribers and 10+ Pharmacies
Oct - Dec 16		
Pain Relievers	88,078	408
Tranquilizers	5,615	0
Stimulants	12,930	0
Sedatives	61,515	0
The sum of Pain Relievers, Tranquilizers, Stimulants, and Sedatives for each Threshold should be less or equal to than the number reported for All Schedule II, III, and/or IV Drugs	168,138	408
All Schedule II, III, and/or IV Drugs: Include the number of Pain Relievers, Tranquilizers, Stimulants and Sedatives, as well as any other Schedule II, III, and/or IV drugs exceeding Thresholds A or B	168,138	408

Performance Measurement	Number of PDMP Reports Produced	
	Jul - Sep 16	Oct - Dec 16
26. Please describe other users to whom reports were sent.		
Jul - Sep 16	Prescribers, pharmacists and their delegates accessed patient reports. Office of Attorney General (noted as Law Enforcement Agency here) accessed the investigative reports and no direct patient reports from the system. PA PDMP office generated reports for patients that requested their own prescription record.	
Oct - Dec 16	Prescribers, pharmacists and their delegates accessed patient reports. Office of Attorney General (noted as Law Enforcement Agency here) accessed the investigative reports and no direct patient reports from the system. Department of State Licensing Board (noted as the regulatory agency) accessed the investigative reports. PA PDMP office generated reports for patients that requested their own prescription record.	

Number of PDMP Reports Produced	Number of Solicited Reports to End Users In-State	Number of Unsolicited Reports to End Users In-State	Number of Solicited Reports to End Users In Another State	Number of Unsolicited Reports to End Users In Another State	Number of Solicited Reports to Another PDMP for End User In Another State	Number of Unsolicited Reports to Another PDMP for End User In Another State
Jul - Sep 16						
26. How many reports did your system produce during the 3-month reporting period?						
Prescribers	443454	0	0	0	0	0
Pharmacies/ Pharmacists	248210	0	0	0	0	0
Law Enforcement	889	0	0	0	0	0
Regulatory Agencies	0	0	0	0	0	0
Patients	9	0	0	0	0	0
Researchers	0	0	0	0	0	0

Medical Examiners / Coroners	0	0	0	0	0	0
Drug Treatment Programs	0	0	0	0	0	0
Drug Court Judges	0	0	0	0	0	0
Others (please describe below)	0	0	0	0	0	0
Total Number of Reports	0	0	0	0	0	0

Number of PDMP Reports Produced	Number of Solicited Reports to End Users In-State	Number of Unsolicited Reports to End Users In-State	Number of Solicited Reports to End Users In Another State	Number of Unsolicited Reports to End Users In Another State	Number of Solicited Reports to Another PDMP for End User In Another State	Number of Unsolicited Reports to Another PDMP for End User In Another State
---------------------------------	---	---	---	---	---	---

Oct - Dec 16						
--------------	--	--	--	--	--	--

Prescribers	699809	0	0	0	0	0
Pharmacies/ Pharmacists	470270	0	0	0	0	0
Law Enforcement	2410	0	0	0	0	0
Regulatory Agencies	0	0	0	0	0	0
Patients	28	0	0	0	0	0
Researchers	0	0	0	0	0	0
Medical Examiners / Coroners	0	0	0	0	0	0
Drug Treatment Programs	0	0	0	0	0	0
Drug Court Judges	0	0	0	0	0	0
Others (please describe below)	0	0	0	0	0	0
Total Number of Reports	0	0	0	0	0	0

Performance Measurement	Number of PDMP Reports Produced	
	Jul - Sep 16	Oct - Dec 16

26. Please explain zero or n/a values entered above. For example, State law and/or policies in regard to unsolicited reports. Enter "N/A" if not applicable.

Jul - Sep 16 No PDMP reports were sent to the users, regulatory agencies or others as the new system was operationalized in August 25, 2016. Definitions to identify the over prescribers, doctor shopping, etc. along with data analysis is still an on-going process. We will collaboratively finalize the methodology of identifying over-prescribers by specialty with Department of State Licensing Boards before we start sending any unsolicited reports out to the prescribers and dispensers.

Oct - Dec 16 No PDMP reports were sent to the users, regulatory agencies or others as the new system was operationalized in August 25, 2016. Definitions to identify the over prescribers, doctor shoppers, outliers, etc.. along with the data analysis is still an on-going process. We will collaboratively finalize the methodology of identifying over-prescribers by specialty with Department of State Licensing Boards before we start sending any unsolicited reports and/or prescriber report cards out to the prescribers and dispensers.

Grantee Comments

Grantee comments were added as follows:

July to September 2016
[No Comments Entered]
October to December 2016
[No Comments Entered]

Narrative

Grantee-level narrative for the period July 1, 2016 - December 31, 2016 were reported as follows:

BJA 7 Questions

Question: What were your accomplishments during reporting period?

Response:

- a. PA PDMP system was successfully transferred from the Office of the Attorney General to Department of Health in May 2016. A continuous communication and outreaches were conducted to all the licensed medical professional informing about this change.
- b. All the dispensers and pharmacies in PA were required to report dispensation data to PA PDMP system within 72 hours of the dispensation as of June 24, 2016. The program office developed list of legislative improvements based on the best practices identified from other states' PDMP legislation. On Nov 2, 2016 an amendment was passed that required the dispensers and pharmacies to report the dispensation data no later than the close of subsequent business day.
- c. Registration for the prescribers and their delegates began August 08, 2016 and the system was available for query to the PDMP system as of August 25, 2016.
- d. The program developed two phases for PDMP education and outreach efforts. Phase one included outreach activities such as email blasts to all the licensed medical professionals, provide online tutorials on how to register, use and assign delegates in the PDMP system. Mass mailings were sent out to all the prescribers and dispensers along with an effort to reach out to all the medical professional societies and hospital and health care system association of PA. Communications were also sent out through social media, TV and Radio PSA's, webinars and PA Health Alert Network. Phase two was developed to deliver face to face education content that will discuss how to effectively use PDMP in the clinical workflows, how to identify red flags, provide effective toolkit examples, how to discuss the disease of addiction with patients and refer the high risk patients to the treatment program and center.
- e. The program office developed champions program that would include members from the medical leadership and clinical practice. The program office is looking to include champions from professional medical societies, hospital and health care systems from both urban and rural areas, academic medical centers, prescribers and dispensers in PA, county and municipal health departments.
- f. In conjunction with PA Medical Society, DOH helped developed continuing medical education units that addresses PA's opioid crisis and includes content related to opioid prescribing guidelines, naloxone, referral to treatment, PA PDMP system and how to identify red flags based on the examples identified from the PA PDMP system.
- g. Program office also developed policies and procedures that are required as per ABC-MAP Act 191.
- h. Communicated resources that are available for prescribers and dispensers to either help patients by placing them in treatment programs or if they identified any fraudulent activities. Resources were also made available on the website as well as on the patient notices at pharmacies that talks about consumer protection line and how patients can get help through local drug and alcohol program initiatives that are in place at county level.
- i. Completed an initial analysis of the PDMP data and overdose death data to identify top priority counties where the face to face education can be provided to all the prescribers.
- j. Initiated a face to face outreach to all the pharmacies in PA to distribute and education about Naloxone standing order, good Samaritan law and PDMP reporting requirements.
- k. Developed PDMP Education Workgroup that will provide recommendation to the program office on the creation and development of innovative and evidence-based education materials for prescribers and dispensers in PA. The group comprises of Physician General's office, Drug and Alcohol Program, ABC-MAP Advisory Committee, Single County Authorities that help place patients to the treatment program or center, health care administrators, clinicians and pharmacists, contractors and evaluators of the program.

Question: What goals were accomplished, as they relate to your grant application?

Response:

- a. Objective 1: Establish and build a data collection and analysis system
 - i. Activity A: Evaluate and secure a vendor of an electronic PDMP system for the purpose of implementing a PDMP system across the Commonwealth.
 - ii. Activity B: Establish reporting guidelines for prescribers and dispensers.
 - iii. Activity C: Facilitate and plan the exchange of controlled substance prescription dispensing information with other states. The implementation of PMPI data sharing will be completed in Q2 2017.
- b. Objective 2: Develop an infrastructure to support programmatic activities
 - i. Activity A: Appoint an Advisory group comprised of dispensers, prescribers, law enforcement officials, addiction specialists, patient and privacy advocates, and individual with expertise considered important to the operation of the program.
 - ii. Recruit and hire program team. The program has a program director, chief technology officer, epidemiologist, and statistical analyst.
- c. Objective 3: Develop a training program for system users
 - i. Activity A: Online PDF tutorials were prepared to help with prescriber, dispenser and delegate registration process. These tutorials also covered education on how to identify red flags and how to navigate through the PDMP system.
- d. Objective 4: Produce and disseminate educational materials
 - i. Activity B: Develop and user-friendly website for the program information.
- e. Objective 5: Assess the efficacy of the ABC-MAP program
 - i. Activity A: Identify and contract with an external evaluator to evaluate the PA PDMP. Through CDC grant, a contract with PHMC was established to conduct program evaluation.

Question: What problems/barriers did you encounter, if any, within the reporting period that prevented you from reaching your goals or milestones?

Response:

- a. Pennsylvania's PDMP system at Department of Health is a new program that was started after a long budget impasse. As the budget impasse was lifted, the selection of a vendor for PDMP system and program director were finalized.
- b. The program office started hiring in April, but with a launch target date of August 2016.
- c. After the launch of the program, the office received about 600+ calls and 200+ emails a week for which, the program brought in six temporary staff to handle them in order to ensure all the authorized prescribers, dispensers and their delegates are registered with the system appropriately.
- d. Additional staff were hired by the program office in Oct 2016, but three more positions need to be filled in order to keep up with the program goals, activities and milestones. Due to a state budget deficit, all state agencies' positions are capped to as they are, therefore a budget justification was provided to DOH Administration as well as Governor's office to ensure that program goals, activities and milestones can be achieved.

Question: Is there any assistance that BJA can provide to address any problems/barriers identified in question #3?

Response:

No

n/a

Question: Are you on track to fiscally and programmatically complete your program as outlined in your grant application? (Please answer YES or NO and if no, please explain.)

Response:
Yes

n/a

Question: What major activities are planned for the next 6 months?

Response:

- a. Continuous communication and outreach regarding legislation requirements, resources for the prescribers, dispensers and the patients, information about treatment programs and centers, and upcoming face to face education initiatives
- b. Plan and execute the face to face education delivery to all the prescribers to prioritized 15 counties in PA.
- c. Ensure that PA's PDMP is inter-connected with all neighboring states as part of PMPi data sharing.
- d. Plan and execute PDMP system integration with Electronic Medical Records (EHR) systems and pharmacy systems in PA.

Question: Based on your knowledge of the criminal justice field, are there any innovative programs/accomplishments that you would like to share with BJA?

Response:

We will brainstorm this with Office of Attorney General's Office and provide an update.

For more information contact BJAPMT@csrincorporated.com
Toll-free Technical Assistance Helpdesk Number: 1-888-252-6867